BR112019021867A2 - Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil - Google Patents
Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil Download PDFInfo
- Publication number
- BR112019021867A2 BR112019021867A2 BR112019021867-0A BR112019021867A BR112019021867A2 BR 112019021867 A2 BR112019021867 A2 BR 112019021867A2 BR 112019021867 A BR112019021867 A BR 112019021867A BR 112019021867 A2 BR112019021867 A2 BR 112019021867A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- phenyl
- hydroxy
- methyl
- acetylamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
a presente invenção provê compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil, a composições farmacêuticas que compreendem os compostos, a métodos de uso dos compostos para tratar distúrbios fisiológicos, tal como câncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382207.3 | 2017-04-18 | ||
| EP17382207 | 2017-04-18 | ||
| PCT/US2018/027005 WO2018194885A1 (en) | 2017-04-18 | 2018-04-11 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019021867A2 true BR112019021867A2 (pt) | 2020-05-26 |
Family
ID=58606227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019021867-0A BR112019021867A2 (pt) | 2017-04-18 | 2018-04-11 | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11655214B2 (pt) |
| EP (2) | EP3612519B1 (pt) |
| JP (2) | JP7110232B2 (pt) |
| KR (2) | KR20230129627A (pt) |
| CN (2) | CN110831927B (pt) |
| AU (2) | AU2018255191B2 (pt) |
| BR (1) | BR112019021867A2 (pt) |
| CO (1) | CO2019012767A2 (pt) |
| CR (1) | CR20190519A (pt) |
| CY (1) | CY1125150T1 (pt) |
| DK (2) | DK4039675T3 (pt) |
| ES (2) | ES2906847T3 (pt) |
| FI (1) | FI4039675T3 (pt) |
| HR (2) | HRP20220263T1 (pt) |
| HU (2) | HUE057745T2 (pt) |
| IL (2) | IL270005B (pt) |
| LT (2) | LT3612519T (pt) |
| MX (2) | MX389724B (pt) |
| MY (1) | MY199442A (pt) |
| NZ (1) | NZ758291A (pt) |
| PH (1) | PH12019502363B1 (pt) |
| PL (2) | PL4039675T3 (pt) |
| PT (2) | PT3612519T (pt) |
| RS (2) | RS65914B1 (pt) |
| SA (1) | SA519410320B1 (pt) |
| SG (1) | SG11201909680UA (pt) |
| SI (2) | SI3612519T1 (pt) |
| SM (2) | SMT202200100T1 (pt) |
| WO (1) | WO2018194885A1 (pt) |
| ZA (1) | ZA201906811B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110831927B (zh) * | 2017-04-18 | 2023-07-14 | 礼来公司 | 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物 |
| BR112020019023A2 (pt) * | 2018-03-26 | 2020-12-29 | Icahn School Of Medicine At Mount Sinai | Métodos de tratamento do câncer residual mínimo |
| WO2021041970A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting imidazolopyrazine compounds |
| US20220348584A1 (en) | 2019-08-29 | 2022-11-03 | Hibercell, Inc. | Perk inhibiting indolinyl compounds |
| WO2021041975A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds |
| US12473296B2 (en) * | 2019-08-29 | 2025-11-18 | Hibercell, Inc. | Perk inhibiting compounds |
| WO2021231782A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibitors for treating viral infections |
| WO2021231788A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds to treat viral infections |
| CN113234029B (zh) * | 2021-05-25 | 2022-03-22 | 白银康寓信生物科技有限公司 | 一种2-氨基-3,5-二卤代吡嗪的合成方法 |
| AU2024242199A1 (en) * | 2023-03-30 | 2025-10-30 | Hibercell, Inc. | Crystalline forms of (r)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-n-isopropylnicotinamide and methods for using the same |
| GB202407386D0 (en) | 2024-05-24 | 2024-07-10 | Apollo Ap45 Ltd | 1H-pyrazolo(4,3-D)pyrimidine derivatives |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| CA2283961A1 (en) | 1997-03-19 | 1998-09-24 | Basf Aktiengesellschaft | Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors |
| TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| AU2003234464B2 (en) | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| PT1663978E (pt) * | 2003-07-23 | 2008-02-15 | Bayer Pharmaceuticals Corp | Omega-carboxiaril difenil ureia substituída por flúor para o tratamento e a prevenção de doenças e estados patológicos |
| PE20070427A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas |
| WO2007026920A2 (en) * | 2005-09-02 | 2007-03-08 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| EP2250498B1 (en) | 2008-02-25 | 2012-10-31 | Prometheus Laboratories Inc. | Drug selection for breast cancer therapy using antibody-based arrays |
| US20120014911A1 (en) | 2009-01-09 | 2012-01-19 | Serge Fuchs | Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor |
| US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
| EP2986286A1 (en) | 2013-04-15 | 2016-02-24 | Universita' Degli Studi di Bari | Galloyl benzamide-based compounds as jnk modulators |
| WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| EP3067356B1 (en) | 2013-11-08 | 2018-07-04 | ONO Pharmaceutical Co., Ltd. | Pyrrolo pyrimidine derivative |
| JP2017507967A (ja) | 2014-03-11 | 2017-03-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｐｅｒｋ阻害剤として作用する化合物 |
| WO2016004254A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| US10221181B2 (en) | 2014-11-14 | 2019-03-05 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| AU2016297754A1 (en) * | 2015-07-24 | 2018-02-15 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to KIT and PDGFR |
| JP6726773B2 (ja) | 2016-07-07 | 2020-07-22 | デウン ファーマシューティカル カンパニー リミテッド | 新規な４−アミノピラゾロ［３，４−ｄ］ピリミジニルアザビシクロ誘導体およびこれを含む薬学組成物 |
| KR20190028540A (ko) | 2016-07-20 | 2019-03-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Perk 억제제로서의 이소퀴놀린 유도체 |
| CN106748989B (zh) | 2016-11-14 | 2020-03-17 | 西安交通大学 | 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用 |
| EP3573608A1 (en) | 2017-01-30 | 2019-12-04 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
| CN110831927B (zh) | 2017-04-18 | 2023-07-14 | 礼来公司 | 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物 |
| KR102740831B1 (ko) | 2017-11-14 | 2024-12-11 | 칠드런'즈 메디컬 센터 코포레이션 | 신규 이미다조피리미딘 화합물 및 그의 용도 |
| EP3492454A1 (en) | 2017-11-30 | 2019-06-05 | Step Pharma S.A.S. | Compounds |
| BR112020019023A2 (pt) | 2018-03-26 | 2020-12-29 | Icahn School Of Medicine At Mount Sinai | Métodos de tratamento do câncer residual mínimo |
| US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| EP3860578A1 (en) | 2018-10-01 | 2021-08-11 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of inhibitors of stress granule formation for targeting the regulation of immune responses |
-
2018
- 2018-04-11 CN CN201880033126.5A patent/CN110831927B/zh active Active
- 2018-04-11 DK DK21211015.9T patent/DK4039675T3/da active
- 2018-04-11 PH PH1/2019/502363A patent/PH12019502363B1/en unknown
- 2018-04-11 KR KR1020237029674A patent/KR20230129627A/ko not_active Ceased
- 2018-04-11 RS RS20240950A patent/RS65914B1/sr unknown
- 2018-04-11 US US16/606,410 patent/US11655214B2/en active Active
- 2018-04-11 HR HRP20220263TT patent/HRP20220263T1/hr unknown
- 2018-04-11 CR CR20190519A patent/CR20190519A/es unknown
- 2018-04-11 RS RS20220154A patent/RS62933B1/sr unknown
- 2018-04-11 HU HUE18718570A patent/HUE057745T2/hu unknown
- 2018-04-11 PT PT187185707T patent/PT3612519T/pt unknown
- 2018-04-11 EP EP18718570.7A patent/EP3612519B1/en active Active
- 2018-04-11 PT PT212110159T patent/PT4039675T/pt unknown
- 2018-04-11 NZ NZ758291A patent/NZ758291A/en unknown
- 2018-04-11 WO PCT/US2018/027005 patent/WO2018194885A1/en not_active Ceased
- 2018-04-11 HR HRP20241188TT patent/HRP20241188T1/hr unknown
- 2018-04-11 EP EP21211015.9A patent/EP4039675B1/en active Active
- 2018-04-11 CN CN202310753648.5A patent/CN117510405A/zh active Pending
- 2018-04-11 DK DK18718570.7T patent/DK3612519T3/da active
- 2018-04-11 LT LTEPPCT/US2018/027005T patent/LT3612519T/lt unknown
- 2018-04-11 SM SM20220100T patent/SMT202200100T1/it unknown
- 2018-04-11 ES ES18718570T patent/ES2906847T3/es active Active
- 2018-04-11 PL PL21211015.9T patent/PL4039675T3/pl unknown
- 2018-04-11 AU AU2018255191A patent/AU2018255191B2/en active Active
- 2018-04-11 SI SI201830572T patent/SI3612519T1/sl unknown
- 2018-04-11 BR BR112019021867-0A patent/BR112019021867A2/pt not_active Application Discontinuation
- 2018-04-11 ES ES21211015T patent/ES2988739T3/es active Active
- 2018-04-11 KR KR1020197033523A patent/KR102575246B1/ko active Active
- 2018-04-11 LT LTEP21211015.9T patent/LT4039675T/lt unknown
- 2018-04-11 HU HUE21211015A patent/HUE068023T2/hu unknown
- 2018-04-11 SM SM20240357T patent/SMT202400357T1/it unknown
- 2018-04-11 SI SI201831149T patent/SI4039675T1/sl unknown
- 2018-04-11 SG SG11201909680U patent/SG11201909680UA/en unknown
- 2018-04-11 MY MYPI2019006116A patent/MY199442A/en unknown
- 2018-04-11 JP JP2019556703A patent/JP7110232B2/ja active Active
- 2018-04-11 MX MX2019012428A patent/MX389724B/es unknown
- 2018-04-11 FI FIEP21211015.9T patent/FI4039675T3/fi active
- 2018-04-11 PL PL18718570T patent/PL3612519T3/pl unknown
-
2019
- 2019-10-16 ZA ZA2019/06811A patent/ZA201906811B/en unknown
- 2019-10-17 IL IL270005A patent/IL270005B/en unknown
- 2019-10-17 SA SA519410320A patent/SA519410320B1/ar unknown
- 2019-10-17 MX MX2022001310A patent/MX2022001310A/es unknown
- 2019-11-15 CO CONC2019/0012767A patent/CO2019012767A2/es unknown
-
2021
- 2021-12-09 IL IL288822A patent/IL288822B2/en unknown
-
2022
- 2022-03-01 CY CY20221100173T patent/CY1125150T1/el unknown
- 2022-07-18 AU AU2022206702A patent/AU2022206702B2/en active Active
- 2022-07-20 JP JP2022115300A patent/JP7331212B2/ja active Active
-
2023
- 2023-04-13 US US18/300,237 patent/US20230373922A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019021867A2 (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| MX2018014154A (es) | Polinucleotidos moduladores. | |
| BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
| BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
| NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
| BR112015023760A2 (pt) | compostos e composições terapêuticas | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| MX2020012132A (es) | Compuestos de azapiridona y usos de los mismos. | |
| BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| MX378108B (es) | Anticuerpos anti-met y composiciones. | |
| CL2017002170A1 (es) | Desacetoxitubulisina h y análogos de esta. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| CO7101239A2 (es) | Composiciones derivadas de la quitosana | |
| BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
| BR112017008867A2 (pt) | inibidores de proteína quinases | |
| BR112017012930A2 (pt) | derivados de imidazopiridazina como inibidores de pi3kbeta. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 213/82 , C07D 487/04 , C07D 239/28 Ipc: C07D 213/82 (2006.01), C07D 487/04 (2006.01), C07D |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |